RajwanthVeluswamyMD

Associate, Medicine - General Internal Medicine, Icahn School of Medicine at Mount Sinai

Dr. Veluswamy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
10 E 102nd St
New York, NY 10029
Phone+1 212-241-6756

Fax+1 212-423-0522

Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2014-2017

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment Start of enrollment: 2020 Jun 29
Completed
Phase 1, Phase 2
Roles: Principal Investigator
Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients Start of enrollment: 2023 Apr 01
Not yet recruiting
Not Applicable
Roles: Contact, Principal Investigator

PubMed

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combin...
Felix Carl Saalfeld, Johanna Möller, Petros Christopoulos, Carina Wenzel, Anna Rasokat
European Journal of Cancer. 2024-12-01
46 citations
An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
Nelson M LaMarche, Samarth Hegde, Matthew D Park, Barbara B Maier, Leanna Troncoso
Nature. 2024-01-01
273 citations
The global burden of lung cancer: current status and future trends.
Amanda Leiter, Rajwanth R Veluswamy, Juan P Wisnivesky
Nature Reviews. Clinical Oncology. 2023-09-01

Lab Notes: Larimar Plans $70M Stock Sale, Gets FDA Clearance to Resume Clinical TestingSeptember 16th, 2022
Onconova Therapeutics Announces Updated Data from Investigator-Sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-Mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022September 13th, 2022
Onconova to Enroll Patients with KRAS-Mutated Lung Cancer in Phase I/II Rigosertib TrialsJune 22nd, 2020
Join now to see all